nasdaq:zyne
|
5360850
|
Apr 14th, 2024 12:00AM
|
Zynerba Pharmaceuticals
|
4.7K
|
15.00
|
Open
|
|
Apr 13th, 2024 11:56PM
|
Apr 13th, 2024 11:56PM
|
Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems.
Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. It also avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and an improved safety profile.
Zynerba’s lead patent-protected product candidate in clinical development is Zygel™. Zygel is the first and only pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. Through a proprietary combination of our pharmaceutically-produced cannabidiol and permeation enhancers, we believe we can effectively deliver CBD through the layers of the epidermis and into the circulatory system. The company is currently assessing Zygel in Fragile X Syndrome, a rare genetic neuropsychiatric syndrome called 22q11.2 Deletion Syndrome, and Autism Spectrum Disorder.
Zynerba is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions. Zynerba is developing a compelling wholly-owned clinical pipeline that may address significant unmet medical needs.
|
Open
|
drug development, cannabinoids, Fragile X Syndrome, Epilepsy, Specialty Pharmaceuticals, Fragile X, and transdermal gel
|
Open
|
80 W. Lancaster Avenue
|
Devon
|
PA
|
US
|
19333
|
|
Zynerba Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:zyne
|
5360850
|
Apr 13th, 2024 12:00AM
|
Zynerba Pharmaceuticals
|
4.7K
|
15.00
|
Open
|
|
Apr 12th, 2024 11:48PM
|
Apr 13th, 2024 12:21PM
|
Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems.
Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. It also avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and an improved safety profile.
Zynerba’s lead patent-protected product candidate in clinical development is Zygel™. Zygel is the first and only pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. Through a proprietary combination of our pharmaceutically-produced cannabidiol and permeation enhancers, we believe we can effectively deliver CBD through the layers of the epidermis and into the circulatory system. The company is currently assessing Zygel in Fragile X Syndrome, a rare genetic neuropsychiatric syndrome called 22q11.2 Deletion Syndrome, and Autism Spectrum Disorder.
Zynerba is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions. Zynerba is developing a compelling wholly-owned clinical pipeline that may address significant unmet medical needs.
|
Open
|
drug development, cannabinoids, Fragile X Syndrome, Epilepsy, Specialty Pharmaceuticals, Fragile X, and transdermal gel
|
Open
|
80 W. Lancaster Avenue
|
Devon
|
PA
|
US
|
19333
|
|
Zynerba Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:zyne
|
5360850
|
Apr 12th, 2024 12:00AM
|
Zynerba Pharmaceuticals
|
4.7K
|
15.00
|
Open
|
|
Apr 11th, 2024 11:55PM
|
Apr 12th, 2024 09:18AM
|
Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems.
Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. It also avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and an improved safety profile.
Zynerba’s lead patent-protected product candidate in clinical development is Zygel™. Zygel is the first and only pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. Through a proprietary combination of our pharmaceutically-produced cannabidiol and permeation enhancers, we believe we can effectively deliver CBD through the layers of the epidermis and into the circulatory system. The company is currently assessing Zygel in Fragile X Syndrome, a rare genetic neuropsychiatric syndrome called 22q11.2 Deletion Syndrome, and Autism Spectrum Disorder.
Zynerba is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions. Zynerba is developing a compelling wholly-owned clinical pipeline that may address significant unmet medical needs.
|
Open
|
drug development, cannabinoids, Fragile X Syndrome, Epilepsy, Specialty Pharmaceuticals, Fragile X, and transdermal gel
|
Open
|
80 W. Lancaster Avenue
|
Devon
|
PA
|
US
|
19333
|
|
Zynerba Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:zyne
|
5360850
|
Apr 11th, 2024 12:00AM
|
Zynerba Pharmaceuticals
|
4.7K
|
15.00
|
Open
|
|
Apr 11th, 2024 12:51AM
|
Apr 11th, 2024 12:02PM
|
Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems.
Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. It also avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and an improved safety profile.
Zynerba’s lead patent-protected product candidate in clinical development is Zygel™. Zygel is the first and only pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. Through a proprietary combination of our pharmaceutically-produced cannabidiol and permeation enhancers, we believe we can effectively deliver CBD through the layers of the epidermis and into the circulatory system. The company is currently assessing Zygel in Fragile X Syndrome, a rare genetic neuropsychiatric syndrome called 22q11.2 Deletion Syndrome, and Autism Spectrum Disorder.
Zynerba is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions. Zynerba is developing a compelling wholly-owned clinical pipeline that may address significant unmet medical needs.
|
Open
|
drug development, cannabinoids, Fragile X Syndrome, Epilepsy, Specialty Pharmaceuticals, Fragile X, and transdermal gel
|
Open
|
80 W. Lancaster Avenue
|
Devon
|
PA
|
US
|
19333
|
|
Zynerba Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:zyne
|
5360850
|
Apr 10th, 2024 12:00AM
|
Zynerba Pharmaceuticals
|
4.7K
|
15.00
|
Open
|
|
Apr 9th, 2024 11:56PM
|
Apr 10th, 2024 06:09PM
|
Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems.
Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. It also avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and an improved safety profile.
Zynerba’s lead patent-protected product candidate in clinical development is Zygel™. Zygel is the first and only pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. Through a proprietary combination of our pharmaceutically-produced cannabidiol and permeation enhancers, we believe we can effectively deliver CBD through the layers of the epidermis and into the circulatory system. The company is currently assessing Zygel in Fragile X Syndrome, a rare genetic neuropsychiatric syndrome called 22q11.2 Deletion Syndrome, and Autism Spectrum Disorder.
Zynerba is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions. Zynerba is developing a compelling wholly-owned clinical pipeline that may address significant unmet medical needs.
|
Open
|
drug development, cannabinoids, Fragile X Syndrome, Epilepsy, Specialty Pharmaceuticals, Fragile X, and transdermal gel
|
Open
|
80 W. Lancaster Avenue
|
Devon
|
PA
|
US
|
19333
|
|
Zynerba Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:zyne
|
5360850
|
Apr 9th, 2024 12:00AM
|
Zynerba Pharmaceuticals
|
4.7K
|
15.00
|
Open
|
|
Apr 9th, 2024 12:07AM
|
Apr 9th, 2024 10:51AM
|
Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems.
Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. It also avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and an improved safety profile.
Zynerba’s lead patent-protected product candidate in clinical development is Zygel™. Zygel is the first and only pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. Through a proprietary combination of our pharmaceutically-produced cannabidiol and permeation enhancers, we believe we can effectively deliver CBD through the layers of the epidermis and into the circulatory system. The company is currently assessing Zygel in Fragile X Syndrome, a rare genetic neuropsychiatric syndrome called 22q11.2 Deletion Syndrome, and Autism Spectrum Disorder.
Zynerba is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions. Zynerba is developing a compelling wholly-owned clinical pipeline that may address significant unmet medical needs.
|
Open
|
drug development, cannabinoids, Fragile X Syndrome, Epilepsy, Specialty Pharmaceuticals, Fragile X, and transdermal gel
|
Open
|
80 W. Lancaster Avenue
|
Devon
|
PA
|
US
|
19333
|
|
Zynerba Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:zyne
|
5360850
|
Apr 8th, 2024 12:00AM
|
Zynerba Pharmaceuticals
|
4.7K
|
15.00
|
Open
|
|
Apr 8th, 2024 01:02AM
|
Apr 8th, 2024 07:48PM
|
Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems.
Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. It also avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and an improved safety profile.
Zynerba’s lead patent-protected product candidate in clinical development is Zygel™. Zygel is the first and only pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. Through a proprietary combination of our pharmaceutically-produced cannabidiol and permeation enhancers, we believe we can effectively deliver CBD through the layers of the epidermis and into the circulatory system. The company is currently assessing Zygel in Fragile X Syndrome, a rare genetic neuropsychiatric syndrome called 22q11.2 Deletion Syndrome, and Autism Spectrum Disorder.
Zynerba is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions. Zynerba is developing a compelling wholly-owned clinical pipeline that may address significant unmet medical needs.
|
Open
|
drug development, cannabinoids, Fragile X Syndrome, Epilepsy, Specialty Pharmaceuticals, Fragile X, and transdermal gel
|
Open
|
80 W. Lancaster Avenue
|
Devon
|
PA
|
US
|
19333
|
|
Zynerba Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:zyne
|
5360850
|
Apr 7th, 2024 12:00AM
|
Zynerba Pharmaceuticals
|
4.7K
|
15.00
|
Open
|
|
Apr 7th, 2024 12:02AM
|
Apr 7th, 2024 12:02AM
|
Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems.
Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. It also avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and an improved safety profile.
Zynerba’s lead patent-protected product candidate in clinical development is Zygel™. Zygel is the first and only pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. Through a proprietary combination of our pharmaceutically-produced cannabidiol and permeation enhancers, we believe we can effectively deliver CBD through the layers of the epidermis and into the circulatory system. The company is currently assessing Zygel in Fragile X Syndrome, a rare genetic neuropsychiatric syndrome called 22q11.2 Deletion Syndrome, and Autism Spectrum Disorder.
Zynerba is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions. Zynerba is developing a compelling wholly-owned clinical pipeline that may address significant unmet medical needs.
|
Open
|
drug development, cannabinoids, Fragile X Syndrome, Epilepsy, Specialty Pharmaceuticals, Fragile X, and transdermal gel
|
Open
|
80 W. Lancaster Avenue
|
Devon
|
PA
|
US
|
19333
|
|
Zynerba Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:zyne
|
5360850
|
Apr 6th, 2024 12:00AM
|
Zynerba Pharmaceuticals
|
4.7K
|
15.00
|
Open
|
|
Apr 6th, 2024 12:01AM
|
Apr 6th, 2024 12:01AM
|
Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems.
Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. It also avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and an improved safety profile.
Zynerba’s lead patent-protected product candidate in clinical development is Zygel™. Zygel is the first and only pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. Through a proprietary combination of our pharmaceutically-produced cannabidiol and permeation enhancers, we believe we can effectively deliver CBD through the layers of the epidermis and into the circulatory system. The company is currently assessing Zygel in Fragile X Syndrome, a rare genetic neuropsychiatric syndrome called 22q11.2 Deletion Syndrome, and Autism Spectrum Disorder.
Zynerba is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions. Zynerba is developing a compelling wholly-owned clinical pipeline that may address significant unmet medical needs.
|
Open
|
drug development, cannabinoids, Fragile X Syndrome, Epilepsy, Specialty Pharmaceuticals, Fragile X, and transdermal gel
|
Open
|
80 W. Lancaster Avenue
|
Devon
|
PA
|
US
|
19333
|
|
Zynerba Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:zyne
|
5360850
|
Apr 5th, 2024 12:00AM
|
Zynerba Pharmaceuticals
|
4.7K
|
15.00
|
Open
|
|
Apr 5th, 2024 01:14AM
|
Apr 5th, 2024 01:14AM
|
Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems.
Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. It also avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and an improved safety profile.
Zynerba’s lead patent-protected product candidate in clinical development is Zygel™. Zygel is the first and only pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. Through a proprietary combination of our pharmaceutically-produced cannabidiol and permeation enhancers, we believe we can effectively deliver CBD through the layers of the epidermis and into the circulatory system. The company is currently assessing Zygel in Fragile X Syndrome, a rare genetic neuropsychiatric syndrome called 22q11.2 Deletion Syndrome, and Autism Spectrum Disorder.
Zynerba is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions. Zynerba is developing a compelling wholly-owned clinical pipeline that may address significant unmet medical needs.
|
Open
|
drug development, cannabinoids, Fragile X Syndrome, Epilepsy, Specialty Pharmaceuticals, Fragile X, and transdermal gel
|
Open
|
80 W. Lancaster Avenue
|
Devon
|
PA
|
US
|
19333
|
|
Zynerba Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|